Acinetobacter — LLMpedia

Contents

Acinetobacter is a genus of Gram-negative, non-motile bacteria notable for environmental ubiquity and clinical importance. First described in the early 20th century, the genus has featured in studies alongside institutions such as Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, European Centre for Disease Prevention and Control and has been the subject of outbreaks investigated by agencies like Public Health England and Johns Hopkins University. Research into the genus has intersected with work at Harvard University, University of Cambridge, Max Planck Society, Institut Pasteur and industrial partners including GlaxoSmithKline.

Taxonomy and morphology

Taxonomic placement of the genus has been revised using criteria developed at International Committee on Systematics of Prokaryotes and sequencing efforts coordinated by consortia such as the Human Microbiome Project and projects at Wellcome Trust Sanger Institute, Broad Institute and European Molecular Biology Laboratory. Classical descriptions used phenotypic schemes from laboratories like American Society for Microbiology and references including the Bergey's Manual of Systematic Bacteriology. Morphologically, species are described in microscopy studies conducted at universities such as Stanford University, Yale University, University of Oxford, University of Tokyo and University of Melbourne, showing coccobacillary to short-rod shapes, lack of flagella, and variable capsule production noted in collections at American Type Culture Collection and Deutsche Sammlung von Mikroorganismen und Zellkulturen.

Physiological profiles have been characterized in metabolic surveys by researchers affiliated with Massachusetts Institute of Technology, California Institute of Technology, Swiss Federal Institute of Technology Zurich, University of California, San Francisco and McGill University, documenting aerobic growth, catalase positivity, and oxidase variability. Genomic analyses from sequencing centers such as Sanger Institute, Broad Institute, J. Craig Venter Institute and European Nucleotide Archive demonstrate diverse genome sizes, plasmid carriage, and horizontal gene transfer events similar to those studied in Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Enterococcus faecalis. Mobile genetic elements and resistance determinants have been tracked using databases maintained by National Center for Biotechnology Information, European Bioinformatics Institute, Centers for Disease Control and Prevention and research teams at Imperial College London.

Members are isolated from soil, water, plant surfaces and animal-associated niches in surveys led by United States Geological Survey, United Nations Environment Programme, Smithsonian Institution and field teams from University of Pretoria, University of Sao Paulo, Peking University and Australian National University. Environmental persistence in hospital plumbing, on surfaces and in dust has been documented in studies associated with Mayo Clinic, Cleveland Clinic, Karolinska Institutet and Tokyo Metropolitan Institute of Public Health, and has relevance to built-environment research at Massachusetts Institute of Technology and Technische Universität Berlin. Interactions with plants and insects have been examined in collaborations involving Royal Botanic Gardens, Kew, USDA, Agricultural Research Service and International Centre for Diarrhoeal Disease Research, Bangladesh.

Certain species are opportunistic pathogens implicated in nosocomial infection outbreaks managed by Centers for Disease Control and Prevention and World Health Organization task forces, with case series reported from hospitals such as Johns Hopkins Hospital, Mayo Clinic Hospital, Mount Sinai Hospital and Royal London Hospital. Clinical manifestations include pneumonia, bloodstream infections and wound infections described in clinical studies at Massachusetts General Hospital, Addenbrooke's Hospital, St Thomas' Hospital and Guy's and St Thomas' NHS Foundation Trust. Virulence factors, biofilm formation and immune interactions have been explored by teams at Fred Hutchinson Cancer Research Center, Dana-Farber Cancer Institute, Johns Hopkins University School of Medicine, University of Toronto and McMaster University. Outbreak investigations have involved public health entities including Public Health Agency of Canada and Agence Régionale de Santé.

Antimicrobial resistance profiles have been characterized in surveillance programs run by World Health Organization, European Centre for Disease Prevention and Control, Centers for Disease Control and Prevention, Asian Development Bank and national reference laboratories such as Public Health England and National Institute for Communicable Diseases. Resistance mechanisms—carbapenemases, efflux pumps and aminoglycoside-modifying enzymes—have parallels with resistance phenomena in Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus faecium and Mycobacterium tuberculosis studied at centers including Johns Hopkins University and Imperial College London. Treatment guidance from organizations such as Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases and national formularies at NHS emphasize combination therapy, stewardship programs evaluated at Mayo Clinic and novel therapeutics in trials at National Institutes of Health, Wellcome Trust and pharmaceutical groups like Pfizer and Roche.

Identification methods include biochemical panels commercialized by companies like bioMérieux, Beckman Coulter, BD Diagnostics and molecular assays developed at Centers for Disease Control and Prevention, Food and Drug Administration and academic laboratories at University of California, Berkeley and University of Washington. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry platforms from Bruker and bioMérieux are used alongside whole-genome sequencing pipelines hosted by European Nucleotide Archive, GenBank and bioinformatics groups at EMBL-EBI and Broad Institute. Typing schemes reference multilocus sequence typing efforts coordinated by research networks at Pasteur Institute, Wellcome Trust Sanger Institute, Public Health England and consortium projects with contributors from Harvard Medical School and Yale School of Medicine.